The Platform of Plasma Users (PLUS) organised its Stakeholder Consensus Conference on January 23-24 in Estoril (Portugal).

The meeting gathered representatives from the following stakeholder organisations: Alpha-1 Belgium, the American Platform of Plasma Users (A-PLUS), the European Blood Alliance (EBA), the European Haemophilia Consortium (EHC), the European Plasma Alliance (EPA), the GBS-CIDP Foundation International, the International Patient Organisation for Primary Immunodeficiencies (IPOPI), the International Plasma and Fractionation Association (IPFA), European Blood Alliance (EBA), Plasma Protein Therapeutics Association (PPTA), World Federation of Haemophilia (WFH),  Marketing Research Bureau (MRB) and Thomas Kluszczynski (ACESO Healthcare Consulting).

During the two-day conference, participants discussed  current priority topics, including:

• An overview of the latest worldwide plasma and plasma-derived medicinal products supply situation;
• The role of the Critical Medicines Alliance in Europe and the procurement and supply of PDMPs;
• Stockpiling in the EU and how this could be applied for PDMPs;
• The ongoing implementation of the regulation on substances of human origin (SoHO) and the current discussions around the pharma legislation;
• The importance of ensuring the safety and efficacy of plasma-derived medicines worldwide.

Several elements were identified as shared interests during the discussions, and participants agreed to continue collaborating on that basis. As a result, some organisations agreed to a joint statement on the safety of PDMPs and to further discussions on the developments of the Critical Medicines Alliance from a plasma-derived medicines perspective